Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.
11 July 2018
Adelaide, Australia, 11 July 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the appointment of Mr. Joaquin Wolff to the position of President, Ellex iTrack™. In this newly created position Mr. Wolff expands the Company’s executive management team and will be dedicated to managing the Ellex iTrack™ business in the rapidly growing minimally invasive glaucoma surgery (MIGS) device market. He will be based out of Ellex iTrack™ headquarters in Fremont in the San Francisco Bay area. Mr. Wolff is a recognized expert in the ophthalmic medical device industry with over 25 years of executive leadership experience. He has held senior management positions in industry- leading companies, including Novartis (Alcon) and Johnson & Johnson (VISX /AMO). In these roles he was responsible for spearheading the launch of several new product platforms in the USA, which attained top market share positions. M
2 July 2018
Adelaide, Australia, 2 July 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the appointment of two new Directors to the Board, Mr. Mike Southard and Mr. Mike Mangano. The appointment will be ratified, by resolution, at the company’s next AGM. Mike Southard Mike Southard spent 25 years with the world’s largest ophthalmology company, Alcon Laboratories of Fort Worth Texas, as Vice President of the Global Surgical business. During Mike’s tenure, the Alcon business grew dramatically from US$85 million to US$2.4 billion of sales per year. Prior to this, he was an executive with Beecham Laboratories (now SmithKline Beecham), and Cooper-Vision, which was acquired by Alcon Laboratories. Mike is currently actively involved in Ophthalmology, Dermatology and Orthopaedics through his consulting company based in Portland, Oregon, USA. He has vast experience in both the International and U.S. markets an
16 April 2018
Highlights: • Sales of Ellex iTrackTM up 57% in the USA and 40% globally compared with the pcp • Improved new customer acquisition and revenues for Ellex iTrackTM in all but one US territory demonstrates improved geographic penetration • Global sales of Ellex glaucoma business reached a record US$22.3 million with an acceleration to 40% growth compared with the pcp Adelaide, Australia 16 April 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced a sales update for Ellex iTrackTM, and its wider glaucoma business, for the 9 months ended 31 March 2018. The wider Ellex glaucoma business comprises the Ellex iTrackTM minimally invasive glaucoma surgery device (MIGS) and the Ellex tangoTM SLT laser for early stage disease. Ellex holds a unique global position for early to mid-stage restorative glaucoma therapy. Ellex iTrackTM Sales Update Ellex iTrackTM global sales were US$6.1 million for the
Annual Report 2017
View Share Price
Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.